QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline

QIAGEN NV, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 39.26 on March 24, 2026. This marks a significant decline, as the stock has experienced a 13.83% decrease over the past year, contrasting sharply with the S&P 500's performance of 13.68% during the same period. The company's market capitalization stands at USD 8,497 million, with a price-to-earnings (P/E) ratio of 18.00. Despite a low debt-to-equity ratio of 0.15, indicating a strong ability to manage debt, QIAGEN has faced challenges in achieving long-term growth, with operating profit increasing at an annual rate of just 5.15% over the last five years. In terms of financial health, QIAGEN reported its highest operating cash flow of USD 675.04 million and a return on capital employed (ROCE) of 10.81% in June 2025. However, the stock's performance has consistently lagged behind the S&P 500 over the last three years, generating a return of -4.29% in the past year while profits rose by 32.2%. The current valuation reflects a discount compared to its peers, with a PEG ratio of 0.6.